Biomimetic Therapeutics Inc

Biomimetic Therapeutics — Investor Day (March 2008)

37 slides from Biomimetic Therapeutics's investor day presentation, Mar 10, 2008

  1. Slide 1: Welcome to the Analyst and Investor Meeting March 6, 2008

    Slide 1: Welcome to the Analyst and Investor Meeting March 6, 2008

    Welcome to the Analyst and Investor Meeting March 6, 2008

  2. Slide 2: Distraction osteogenesis technique for lengthening a long bone

    Slide 2: Distraction osteogenesis technique for lengthening a long bone

    Distraction osteogenesis is a technique for lengthening a long bone Used to fill large bony defects caused by: Traumatic segmental bone loss Congenital and acquired limb length discrepancy Deformity Chronic medical conditions (i.e. osteomyelitis) Rat Distraction Osteogenesis Model

  3. Slide 3: Study Hypothesis

    Slide 3: Study Hypothesis

    Study Hypothesis Exogenous rhPDGF-BB will increase new bone formation Rate of healing (bone union) will increase with rhPDGF- BB administration The quantity of new bone formation will increase in a dose dependent manner with rhPDGF-BB

  4. Slide 4: Distraction Osteogenesis Rat Model (RIH)

    Slide 4: Distraction Osteogenesis Rat Model (RIH)

    Model Mid-diaphyseal femoral lengthening Seven day latency period 7 mm lengthening over 21 days 2 x 0.17 mm per day Treatments Buffer Injectable Collagen + Buffer Injectable Collagen + rhPDGF-BB (100 ug/ml) Injectable Collagen + rhPDGF-BB (300 ug/ml) Injectable Collagen + rhPDGF-BB (1000 ug/ml) Outc

  5. Slide 5: Treatment and Data Acquisition Scheme for All Groups

    Slide 5: Treatment and Data Acquisition Scheme for All Groups

    Treatment and Data Acquisition Scheme for All Groups Distraction (shaded) Day 1 7 14 21 28 35 42 49 56 63 Injection: ? ? ? ? Faxitron X-ray ? ? ? ? ? ? ? ? ? µCT & Histology (n=3/pt) ? ? ? ? ? Distraction Osteogenesis Rat Model (RIH) Day 35

  6. Slide 6: Progressive Bone Formation and Consolidation

    Slide 6: Progressive Bone Formation and Consolidation

    Progressive Bone Formation and Consolidation Day 35 Day 42 Day 56 Day 63 (Specimen B74 - 1,000 µg/ml rhPDGF-BB)

  7. Slide 7: Comparative Evaluation of Treatment Groups

    Slide 7: Comparative Evaluation of Treatment Groups

    Comparative Evaluation of Treatment Groups at Day 49

  8. Slide 8: Radiographs and µCT images from an animal treated with rhPDGF-BB

    Slide 8: Radiographs and µCT images from an animal treated with rhPDGF-BB

    Radiographs and µCT images from an animal treated with 300 µg/ml rhPDGF-BB. A) Day 28 (completion of distraction). B) Day 63 (euthanasia). C) µCT image, spanning inner two pins. D) µCT image in center of distraction gap A B C D

  9. Slide 9: MicroCT Analysis of Distracted Rat Femurs

    Slide 9: MicroCT Analysis of Distracted Rat Femurs

    *Significantly different from combined controls MicroCT Analysis of Distracted Rat Femurs

  10. Slide 10: MicroCT Analysis of Distracted Rat Femurs

    Slide 10: MicroCT Analysis of Distracted Rat Femurs

    *Significantly different from combined controls MicroCT Analysis of Distracted Rat Femurs

  11. Slide 11: Overall, Union Rate Increased with rhPDGF-BB Treatment

    Slide 11: Overall, Union Rate Increased with rhPDGF-BB Treatment

    Overall, Union Rate Increased with rhPDGF-BB Treatment µCT Assessed Bone Union µCT Assessed Bone Union µCT Assessed Bone Union µCT Assessed Bone Union µCT Assessed Bone Union µCT Assessed Bone Union Day Buffer Collagen 100 µg/ml rhPDGF-BB 300 µg/ml rhPDGF-BB 1,000 µg/ml rhPDGF-BB 35 0/3 0/1 0/3 0/3

  12. Slide 12: Conclusions

    Slide 12: Conclusions

    Conclusions Treatment with rhPDGF-BB in bovine collagen Significantly increased mid-consolidation new bone formation Significantly increased overall union rate

  13. Slide 13: Diabetic Rat Model (UMDNJ)

    Slide 13: Diabetic Rat Model (UMDNJ)

    Diabetic Rat Model (UMDNJ) Homology with Type I diabetes Mimics human setting for compromised healing Male BB Wistar rats - spontaneous onset of diabetes Incidence rate of 50% at 85 days Insulitis with beta-cell destruction Lethal within 5-10 days if not treated Treatment with insulin implant Mainta

  14. Slide 14: Diabetic Rat Bone Augmentation Pilot Study

    Slide 14: Diabetic Rat Bone Augmentation Pilot Study

    Model Diabetic female rats (~2 weeks post diabetic) Unilateral intramedullary injection into the femur Treatments 0.3 mg/ml rhPDGF-BB + Collagen/b-TCP matrix "GEM OS2" Contralateral side - no injection Outcome Measurement - 5 weeks post treatment uCT Histology Diabetic Rat Bone Augmentation Pilot St

  15. Slide 15: Intramedullary Injection of GEM OS2 Increases Cortical Thickness

    Slide 15: Intramedullary Injection of GEM OS2 Increases Cortical Thickness

    Intramedullary Injection of GEM OS2 into the Femur of Diabetic Rats Increases Cortical Thickness- Pilot Study (UMDNJ) Cortical Thickness Analysis Buffer + Matrix Untreated Control % Change +7.5 Untreated Control % Change +32.9 PDGF 0.3 mg/ml + Matrix

  16. Slide 16: GEMOS2 Injection Causes Formation of Periosteal Woven Bone

    Slide 16: GEMOS2 Injection Causes Formation of Periosteal Woven Bone

    GEMOS2 Injection Causes Formation of Periosteal Woven Bone Uninjected GEM OS2 0.3 mg/ml PDGF

  17. Slide 17: Non-Human Primate Spine Bone Augmentation Study

    Slide 17: Non-Human Primate Spine Bone Augmentation Study

    Non-Human Primate Spine Bone Augmentation Study

  18. Slide 18: Localized Bone Augmentation Concept

    Slide 18: Localized Bone Augmentation Concept

    Localized Bone Augmentation Concept - Stimulate focal enhancement of new bone formation in osteoporotic bones (e.g., vertebral body) Hypothesis -Treatment with rhPDGF-BB in an injectable matrix (GEM OS2) will lead to localized bone formation

  19. Slide 19: GEM OS2 Primate Spine Safety Study

    Slide 19: GEM OS2 Primate Spine Safety Study

    Model Aged female baboons (~17 - 21 years old) Direct injection into the vertebral body Treatments 1.0 mg/ml rhPDGF-BB + Collagen/b-TCP matrix "GEM OS2" Buffer + Collagen/b-TCP matrix Buffer alone Outcome Measurements - pre-op, post-op, 1, 3, 6 & 9 months In-Life Outcomes: MRI, QCT, X-rays, Clinical

  20. Slide 20: GEM OS2 Primate Spine Safety Study

    Slide 20: GEM OS2 Primate Spine Safety Study

    GEM OS2 Primate Spine Safety Study

  21. Slide 21: Animal #9055, rhPDGF-BB + matrix

    Slide 21: Animal #9055, rhPDGF-BB + matrix

    Animal #9055, rhPDGF-BB + matrix Pre-op Post-op 1-month 3-month 6-month T12 L2 L4 L6

  22. Slide 22: GEM OS2 Injection Increases vBMD Post-surgery

    Slide 22: GEM OS2 Injection Increases vBMD Post-surgery

    GEM OS2 Injection Increases vBMD out to 9 Months Post-surgery

  23. Slide 23: Summary - Bone Augmentation with rhPDGF-BB

    Slide 23: Summary - Bone Augmentation with rhPDGF-BB

    Appears safe - no signs of local or systemic toxicity Significantly enhanced bone density by 12 weeks which was maintained out to 36 weeks rhPDGF-BB + GEM OS2 matrix is a viable therapeutic option to enhance bone formation in osteoporotic vertebral bodies Summary - Bone Augmentation with rhPDGF-BB

  24. Slide 24: Seven Ongoing Trials in Orthopedics

    Slide 24: Seven Ongoing Trials in Orthopedics

    Seven Ongoing Trials in Orthopedics GEM OS1 Stage Status Foot and Ankle Fusion US Pilot Positive results Canadian Pilot/Pivotal Positive results US Pivotal Enrolling EU Pivotal Enrolling Distal Radius Fx EU Pilot Positive results GEM OS2 Foot and Ankle Fusion Canadian Pilot Data anticipated H2 08 Di

  25. Slide 25: US Pivotal GEM OS1 Clinical Trial

    Slide 25: US Pivotal GEM OS1 Clinical Trial

    US Pivotal GEM OS1 Clinical Trial 28 centers - 28 centers approved for enrollment 396 patients - 125 patients randomized and enrolled Randomized 2:1 (GEM OS1 : Autograft) Primary endpoint - % fusion by CT scans at 6 months Non-inferiority to autograft Enrollment ongoing - Anticipate enrollment to be

  26. Slide 26: EU Pivotal GEM OS1 Clinical Trial

    Slide 26: EU Pivotal GEM OS1 Clinical Trial

    EU Pivotal GEM OS1 Clinical Trial Up to 10 centers - 7 centers approved for enrollment 125 patients - 65 patients enrolled Open label study (GEM OS1) Primary endpoint - % fusion by CT scans at 9 months Enrollment ongoing - Anticipate completing enrollment in Fall 2008 Foot & Ankle Fusions

  27. Slide 27: Canadian GEM OS1 Registration Clinical Trial

    Slide 27: Canadian GEM OS1 Registration Clinical Trial

    Canadian GEM OS1 Registration Clinical Trial 3 centers 60 patients Open label study (GEM OS1) Primary endpoint - % fusion at 9 months Enrollment completed Foot & Ankle Fusions

  28. Slide 28: Canadian GEM OS1 Registration Clinical Trial Filing Status

    Slide 28: Canadian GEM OS1 Registration Clinical Trial Filing Status

    Canadian GEM OS1 Registration Clinical Trial Filing Status - Based upon ongoing conversations with Health Canada related to the filing of the DLA, the need to hold a face-to-face meeting with BioMimetic has been eliminated. The Company is addressing comments provided by Health Canada and intends to

  29. Slide 29: Summary of N. American Foot and Ankle rhPDGF Clinical Trials

    Slide 29: Summary of N. American Foot and Ankle rhPDGF Clinical Trials

    Summary of N. American Foot and Ankle rhPDGF Clinical Trials United States Canada Number of Centers 3 3 Number of Subjects 20 60 Type of Study Randomized, Controlled Open-Label (GEM OS1 only) Control Autograft None Inclusion Criteria Ankle/Hindfoot Midfoot/Hindfoot/Ankle Primary Endpoint Radiographi

  30. Slide 30: Patient Demographics

    Slide 30: Patient Demographics

    Patient Demographics US Autograft N=6 US GEM OS1 N=14 CAN GEM OS1 N=60 Patient Age 43.7 55.2 53.4 Body Mass Index 30.5 29.8 29.0 % Smoking history 17% 50% 60% Revision - - 33% Injury/Deformity 83% PTI 17% PA 0% RA 64% PTI 14% PA 14% RA 14% Other 33% PTI 35% PA 10% RA 30

  31. Slide 31: Types of Procedures Performed

    Slide 31: Types of Procedures Performed

    US Autograft (N=6) US GEM OS1 (N=14) CAN GEM OS1 (N=60) Ankle/Hindfoot 6 (100%) 14 (100%) 34 (57%) Ankle 2 (33%) 5 (36%) 10 (17%) Subtalar 1 (17%) 3 (21%) 7 (12%) Triple 3 (50%) 6 (43%) 14 (23%) Other Isolated Hindfoot 0 (0%) 0 (0%) 5 (8%) Midfoot/Forefoot 0 (0%) 0 (0%) 29 (48%) Total # of Joints Tr

  32. Slide 32: Results: Radiographic and Clinical Union

    Slide 32: Results: Radiographic and Clinical Union

    United States United States Canada CT1 ABG GEM OS1 GEM OS1 Week 6 33% 39% 43% Week 12 50% 69% 68% Radiographs2 Week 24 80% 100% 84% Clinical Success Week 24 100% 85% 90% Results: Radiographic and Clinical Union Independent Radiologist Assessment: 1. Fusion on CT: Bridging bone ^ 50% across joint 2.

  33. Slide 33: Results: Safety and AOFAS Scores

    Slide 33: Results: Safety and AOFAS Scores

    United States United States Canada* AOFAS ABG GEM OS1 GEM OS1 Baseline 36.3 39.2 41.7 Week 24 74.2 66.0 64.9 Results: Safety and AOFAS Scores No device related SAEs reported to date *Hindfoot / ankle only 33

  34. Slide 34: Results: Donor Site Pain and Procedure Time

    Slide 34: Results: Donor Site Pain and Procedure Time

    United States United States Canada ABG GEM OS1 GEM OS1 Fusion Site Pain (VAS) Week 12 22.2 17.3 N/A Donor Site Pain (VAS) Week 12 14.9 0 0 Procedure Time (minutes) 144 118 105 Results: Donor Site Pain and Procedure Time 34

  35. Slide 35: Discussion

    Slide 35: Discussion

    Discussion In addressing difficult bone healing challenges, we need to pay careful attention to basic bone biology Non-unions in foot/ankle fusions remain unacceptably high, particularly in patients with one or more risk factors These studies compared rhPDGF + ^-TCP matrix (GEM OS1) to ABG in a tota

  36. Slide 36: Discussion

    Slide 36: Discussion

    Discussion Results achieved with rhPDGF/TCP were comparable to published ABG data US and Canadian studies produced similar results rhPDGF treated patients were spared pain and morbidity of bone graft harvest rhPDGF treated patients experienced shorter operative time, by approximately 30 minutes 38

  37. Slide 37: Conclusions

    Slide 37: Conclusions

    Conclusions GEM OS1 appears to be a safe and effective alternative to ABG without graft harvest morbidity The results of this trial have led to an FDA approved, 396 patient, 28 center RCT Study Challenges/Lessons Learned Standard x-rays are not the best tool to evaluate fusion progress; pivotal stud

Source: SEC EDGAR · 8-K filed Mar 10, 2008

More decks from Biomimetic Therapeutics Inc